End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.09 CNY | -0.88% | -2.13% | -6.83% |
Apr. 29 | Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024 | MT |
Apr. 26 | Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- Based on current prices, the company has particularly high valuation levels.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.83% | 2.75B | C | ||
-3.57% | 87.06B | A- | ||
+2.76% | 40.25B | A- | ||
-17.49% | 31.09B | B- | ||
+54.44% | 24.74B | A | ||
-13.13% | 15.91B | C | ||
-9.12% | 11.96B | D+ | ||
-15.45% | 11.92B | B- | ||
-42.56% | 11.61B | B | ||
+4.87% | 8.73B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 600867 Stock
- Ratings Tonghua Dongbao Pharmaceutical Co., Ltd.